Osaic Holdings
SVA

Osaic Holdings’s Sinovac Biotech, Ltd SVA Stock Holding History

Osaic Holdings’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Buy
2,201
+213
+11% – ﹤0.01% 8142
2025
Q4 		$0 Sell
1,988
-164
-8% – ﹤0.01% 8309
2025
Q3 		$0 Buy
2,152
+71
+3% – ﹤0.01% 8079
2025
Q2 		$0 Buy
+2,081
New – ﹤0.01% 7968
2024
Q3 		– Sell
-201
Closed – – 7723
2024
Q2 		$0 Buy
+201
New – ﹤0.01% 7726
2023
Q4 		– Sell
-1,362
Closed – – 7661
2023
Q3 		$0 Hold
1,362
– – ﹤0.01% 7720
2023
Q2 		$0 Buy
+1,362
New – ﹤0.01% 7754
2022
Q4 		– Sell
-1,364
Closed – – 7801
2022
Q3 		$0 Hold
1,364
– – ﹤0.01% 7829
2022
Q2 		$0 Buy
+1,364
New – ﹤0.01% 7914
2022
Q1 		– Sell
-1,362
Closed – – 7857
2021
Q4 		$0 Hold
1,362
– – ﹤0.01% 7899
2021
Q3 		$0 Hold
1,362
– – ﹤0.01% 7584
2021
Q2 		$0 Hold
1,362
– – ﹤0.01% 7369
2021
Q1 		$0 Hold
1,362
– – ﹤0.01% 7165
2020
Q4 		$0 Hold
1,362
– – ﹤0.01% 6842
2020
Q3 		$0 Hold
1,362
– – ﹤0.01% 6652
2020
Q2 		$0 Sell
1,362
-4
-0.3% – ﹤0.01% 6599
2020
Q1 		$0 Buy
+1,366
New – ﹤0.01% 6332

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Osaic Holdings's SVA Position: Q1 2026 in Review

Osaic Holdings increased its Sinovac Biotech, Ltd (SVA) stake by 11% in Q1 2026, adding 213 shares and bringing the position to 2,201 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #8142.

Osaic Holdings first reported a position in SVA in Q1 2020 and has held it in 17 quarters since. 28 funds tracked by Wall St. Rank hold SVA as of Q1 2026.

  • Osaic Holdings held 2,201 shares of Sinovac Biotech, Ltd worth $0 as of Q1 2026.
  • Osaic Holdings bought 213 Sinovac Biotech, Ltd shares in Q1 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #8142 holding.
  • Osaic Holdings first reported a position in Sinovac Biotech, Ltd in Q1 2020 and has held it in 17 quarters since.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.